AMRI 22.89 Albany Molecular Research $AMRI Hit a 5
Post# of 18
Posted On: 11/03/2014 10:11:40 PM
AMRI 22.89 Albany Molecular Research $AMRI Hit a 52 week high of 23.95 Closing the day 11/03/14 at 22.89 -0.37 -1.59% With a day low of 22.50 and a total volume of 515,289.
AMRI Recent Posts: http://investorshangout.com/Albany-Molecular-...MRI-53313/
AMRI Albany Molecular Research Recent Headline News
AMRI CEO to Present at the 2014 Credit Suisse Healthcare Conference
PR Newswire - Wed Oct 29, 7:00AM CDT
Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at the 2014 Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 2:00 p.m. MT.
AMRI: 22.89 (-0.37)
AMRI to Announce Third Quarter Results on November 5, 2014
PR Newswire - Fri Oct 24, 7:00AM CDT
AMRI (NASDAQ: AMRI) today announced it will issue third quarter financial results before the opening of the U.S. financial markets on Wednesday, November 5, 2014. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 8:30 a.m. ET.
AMRI: 22.89 (-0.37)
3 Biotech Stocks With Humongous Short Interest
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 22, 8:05AM CDT
Buying when everyone else is scared may sound like a fantastic way to buy great companies at bargain-basement prices, but it can be tricky to figure out when there's enough fear to justify buying, especially in hit-and-miss industries...
EBS: 22.31 (-0.31), NLNK: 32.61 (-0.04), TEVA: 57.80 (+1.33), AMRI: 22.89 (-0.37)
Trade-Ideas: Albany Molecular Research (AMRI) Is Today's Strong And Under The Radar Stock
at The Street - Wed Sep 24, 2:06PM CDT
Trade-Ideas LLC identified Albany Molecular Research (AMRI) as a strong and under the radar candidate
AMRI: 22.89 (-0.37)
Insider Trading Alert - BRCM, CI And AMRI Traded By Insiders
at The Street - Mon Sep 15, 9:45AM CDT
Stocks with insider trader activity include BRCM, CI and AMRI
CI: 99.73 (+0.16), BRCM: 41.80 (-0.08), AMRI: 22.89 (-0.37)
Albany Molecular Research (AMRI) Is Today's Strong And Under The Radar Stock
at The Street - Mon Sep 15, 9:28AM CDT
Trade-Ideas LLC identified Albany Molecular Research (AMRI) as a strong and under the radar candidate
AMRI: 22.89 (-0.37)
Albany Molecular Resh (AMRI) Upgraded From Hold to Buy
at The Street - Thu Sep 11, 7:56AM CDT
Albany Molecular Resh (AMRI) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B-.
AMRI: 22.89 (-0.37)
New Platforms Enhance AMRI's Discovery Biology Offerings
PR Newswire Europe - Thu Sep 04, 7:01AM CDT
AMRI announced today that it has expanded into the protein market, with an initial focus on protein expression and purification. The global revenue of the total proteomics market is anticipated to grow at a compound annual growth rate of about 4.1% to about $9.2 billion by 2018(1).
AMRI: 22.89 (-0.37)
AMRI CEO to Present at the Morgan Stanley Global Healthcare Conference
PR Newswire Europe - Tue Aug 26, 7:02AM CDT
Albany Molecular Research Inc. announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 8:45 a.m. ET.
AMRI: 22.89 (-0.37), MS: 34.71 (-0.24)
Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014
M2 - Tue Aug 19, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvjp7j/pharmaceutical) has announced the addition of the "Pharmaceutical Contract Manufacturing - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms: Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 92 companies including many key and niche players such as: - AAIPharma Services Corporation - Aenova Group - Ajinomoto Althea, Inc. - Albany Molecular Research, Inc. - Dishman Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS - Study Reliability and Reporting Limitations - Disclaimers - Data Interpretation & Reporting Level - Quantitative Techniques & Analytics - Product Definitions and Scope of Study II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS & ISSUES 3. COMPETITIVE LANDSCAPE 4. SERVICE OVERVIEW 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT GLOBAL PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 92 The United States (34) - Canada (3) - Japan (4) - Europe (33) - France (3) - Germany (
- The United Kingdom (9) - Italy (3) - Rest of Europe (10) - Asia-Pacific (Excluding Japan) (18) For more information visit http://www.researchandmarkets.com/research/dv...maceutical
AMRI: 22.89 (-0.37)
Albany Molecular Research Inc. Co-Founder Thomas D'Ambra Joins ACPHS Board of Trustees
Marketwire - Wed Aug 06, 10:55AM CDT
Albany College of Pharmacy and Health Sciences (ACPHS) announced today that Thomas D'Ambra, Ph.D., co-founder of Albany Molecular Research Inc. (NASDAQ: AMRI), has been appointed to the College's Board of Trustees.
AMRI: 22.89 (-0.37)
Nasdaq stocks posting largest percentage increases
AP - Tue Aug 05, 12:21PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
DRTX: 24.03 (unch), ANY: 5.65 (-0.01), ISRL: 131.54 (+0.54), LGND: 56.49 (+1.22), RPRX: 6.50 (+0.16), AMRI: 22.89 (-0.37), RDUS: 19.02 (+0.61), TTS: 8.67 (+0.06), RNA: 12.60 (+0.81), ANIP: 41.20 (+7.24), CNIT: 3.90 (-0.07), JST: 7.70 (+0.02), QLYS: 32.68 (+0.60), JMBA: 13.34 (-0.01)
AMRI Announces Second Quarter 2014 Results
PR Newswire Europe - Tue Aug 05, 6:51AM CDT
- Total Revenue of $68.2 million, including Contract Revenue of $61.5 Million, up 15%
AMRI: 22.89 (-0.37)
Uptrend Call Working As Albany Molecular Research Stock Rises 12.9% (AMRI)
Comtex SmarTrend(R) - Thu Jul 31, 9:23AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on June 3rd, 2014 at $17.04. In approximately 2 months, Albany Molecular Research has returned 12.85% as of today's recent price of $19.23.
AMRI: 22.89 (-0.37)
19.1% Return Seen to Date on SmarTrend Albany Molecular Research Call (AMRI)
Comtex SmarTrend(R) - Thu Jul 24, 9:26AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on June 3rd, 2014 at $17.04. In approximately 2 months, Albany Molecular Research has returned 19.13% as of today's recent price of $20.30.
AMRI: 22.89 (-0.37)
AMRI to Announce Second Quarter Results
PR Newswire Europe - Tue Jul 22, 7:00AM CDT
AMRI today announced it will issue second quarter financial results before the opening of the market on Tuesday, August 5, 2014. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 10:00 a.m. ET.
AMRI: 22.89 (-0.37)
AMRI Recent Posts: http://investorshangout.com/Albany-Molecular-...MRI-53313/
AMRI Albany Molecular Research Recent Headline News
AMRI CEO to Present at the 2014 Credit Suisse Healthcare Conference
PR Newswire - Wed Oct 29, 7:00AM CDT
Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at the 2014 Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 2:00 p.m. MT.
AMRI: 22.89 (-0.37)
AMRI to Announce Third Quarter Results on November 5, 2014
PR Newswire - Fri Oct 24, 7:00AM CDT
AMRI (NASDAQ: AMRI) today announced it will issue third quarter financial results before the opening of the U.S. financial markets on Wednesday, November 5, 2014. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 8:30 a.m. ET.
AMRI: 22.89 (-0.37)
3 Biotech Stocks With Humongous Short Interest
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 22, 8:05AM CDT
Buying when everyone else is scared may sound like a fantastic way to buy great companies at bargain-basement prices, but it can be tricky to figure out when there's enough fear to justify buying, especially in hit-and-miss industries...
EBS: 22.31 (-0.31), NLNK: 32.61 (-0.04), TEVA: 57.80 (+1.33), AMRI: 22.89 (-0.37)
Trade-Ideas: Albany Molecular Research (AMRI) Is Today's Strong And Under The Radar Stock
at The Street - Wed Sep 24, 2:06PM CDT
Trade-Ideas LLC identified Albany Molecular Research (AMRI) as a strong and under the radar candidate
AMRI: 22.89 (-0.37)
Insider Trading Alert - BRCM, CI And AMRI Traded By Insiders
at The Street - Mon Sep 15, 9:45AM CDT
Stocks with insider trader activity include BRCM, CI and AMRI
CI: 99.73 (+0.16), BRCM: 41.80 (-0.08), AMRI: 22.89 (-0.37)
Albany Molecular Research (AMRI) Is Today's Strong And Under The Radar Stock
at The Street - Mon Sep 15, 9:28AM CDT
Trade-Ideas LLC identified Albany Molecular Research (AMRI) as a strong and under the radar candidate
AMRI: 22.89 (-0.37)
Albany Molecular Resh (AMRI) Upgraded From Hold to Buy
at The Street - Thu Sep 11, 7:56AM CDT
Albany Molecular Resh (AMRI) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B-.
AMRI: 22.89 (-0.37)
New Platforms Enhance AMRI's Discovery Biology Offerings
PR Newswire Europe - Thu Sep 04, 7:01AM CDT
AMRI announced today that it has expanded into the protein market, with an initial focus on protein expression and purification. The global revenue of the total proteomics market is anticipated to grow at a compound annual growth rate of about 4.1% to about $9.2 billion by 2018(1).
AMRI: 22.89 (-0.37)
AMRI CEO to Present at the Morgan Stanley Global Healthcare Conference
PR Newswire Europe - Tue Aug 26, 7:02AM CDT
Albany Molecular Research Inc. announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 8:45 a.m. ET.
AMRI: 22.89 (-0.37), MS: 34.71 (-0.24)
Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014
M2 - Tue Aug 19, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvjp7j/pharmaceutical) has announced the addition of the "Pharmaceutical Contract Manufacturing - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms: Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 92 companies including many key and niche players such as: - AAIPharma Services Corporation - Aenova Group - Ajinomoto Althea, Inc. - Albany Molecular Research, Inc. - Dishman Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS - Study Reliability and Reporting Limitations - Disclaimers - Data Interpretation & Reporting Level - Quantitative Techniques & Analytics - Product Definitions and Scope of Study II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS & ISSUES 3. COMPETITIVE LANDSCAPE 4. SERVICE OVERVIEW 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT GLOBAL PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 92 The United States (34) - Canada (3) - Japan (4) - Europe (33) - France (3) - Germany (
- The United Kingdom (9) - Italy (3) - Rest of Europe (10) - Asia-Pacific (Excluding Japan) (18) For more information visit http://www.researchandmarkets.com/research/dv...maceutical AMRI: 22.89 (-0.37)
Albany Molecular Research Inc. Co-Founder Thomas D'Ambra Joins ACPHS Board of Trustees
Marketwire - Wed Aug 06, 10:55AM CDT
Albany College of Pharmacy and Health Sciences (ACPHS) announced today that Thomas D'Ambra, Ph.D., co-founder of Albany Molecular Research Inc. (NASDAQ: AMRI), has been appointed to the College's Board of Trustees.
AMRI: 22.89 (-0.37)
Nasdaq stocks posting largest percentage increases
AP - Tue Aug 05, 12:21PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
DRTX: 24.03 (unch), ANY: 5.65 (-0.01), ISRL: 131.54 (+0.54), LGND: 56.49 (+1.22), RPRX: 6.50 (+0.16), AMRI: 22.89 (-0.37), RDUS: 19.02 (+0.61), TTS: 8.67 (+0.06), RNA: 12.60 (+0.81), ANIP: 41.20 (+7.24), CNIT: 3.90 (-0.07), JST: 7.70 (+0.02), QLYS: 32.68 (+0.60), JMBA: 13.34 (-0.01)
AMRI Announces Second Quarter 2014 Results
PR Newswire Europe - Tue Aug 05, 6:51AM CDT
- Total Revenue of $68.2 million, including Contract Revenue of $61.5 Million, up 15%
AMRI: 22.89 (-0.37)
Uptrend Call Working As Albany Molecular Research Stock Rises 12.9% (AMRI)
Comtex SmarTrend(R) - Thu Jul 31, 9:23AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on June 3rd, 2014 at $17.04. In approximately 2 months, Albany Molecular Research has returned 12.85% as of today's recent price of $19.23.
AMRI: 22.89 (-0.37)
19.1% Return Seen to Date on SmarTrend Albany Molecular Research Call (AMRI)
Comtex SmarTrend(R) - Thu Jul 24, 9:26AM CDT
SmarTrend identified an Uptrend for Albany Molecular Research (NASDAQ:AMRI) on June 3rd, 2014 at $17.04. In approximately 2 months, Albany Molecular Research has returned 19.13% as of today's recent price of $20.30.
AMRI: 22.89 (-0.37)
AMRI to Announce Second Quarter Results
PR Newswire Europe - Tue Jul 22, 7:00AM CDT
AMRI today announced it will issue second quarter financial results before the opening of the market on Tuesday, August 5, 2014. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 10:00 a.m. ET.
AMRI: 22.89 (-0.37)
(0)
(0)Albany Molecular Research (AMRI) Stock Research Links
Scroll down for more posts ▼